

Gabriela Hernandez-Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1417055/publications.pdf>

Version: 2024-02-01

85
papers

2,336
citations

304602

22
h-index

233338

45
g-index

90
all docs

90
docs citations

90
times ranked

2999
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous cholecystocutaneous fistula as the presenting manifestation of IgG4-related disease. <i>Surgery</i> , 2022, 171, e17-e18.	1.0	1
2	IgG4-Related Disease. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e596-e604.	0.5	16
3	Chemokine tear levels in primary Sjögren's syndrome and their relationship with symptoms. <i>International Ophthalmology</i> , 2022, 42, 2355-2361.	0.6	5
4	Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes. <i>Current Rheumatology Reviews</i> , 2022, 18, 272-277.	0.4	5
5	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	0.9	12
6	Total body water and sicca symptoms in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1
7	Clinical and Serological Features in Latin American IgG4-Related Disease Patients Differ According to Sex, Ethnicity, and Clinical Phenotype. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 285-292.	0.5	3
8	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021, 60, 2946-2957.	0.9	15
9	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , 2021, 60, 4558-4567.	0.9	24
10	Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease. <i>Scientific Reports</i> , 2021, 11, 1832.	1.6	6
11	What is the meaning of ANCA positivity in IgG4-related disease?. <i>Rheumatology</i> , 2021, 60, 3845-3850.	0.9	14
12	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	1.3	4
13	Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios. <i>Thrombosis Research</i> , 2021, 203, 12-17.	0.8	3
14	Parotid gland swelling in primary Sjögren's syndrome: activity and other sialadenosis causes. <i>Rheumatology</i> , 2021, , .	0.9	0
15	Factors influencing the EULAR Sjögren's Syndrome Patient Reported Index in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
16	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
17	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
18	Factors influencing the EULAR Sjögren's Syndrome Patient-Reported Index in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 153-158.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 49-56.	0.4	1
20	New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. <i>Cells</i> , 2021, 10, 3592.	1.8	135
21	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.4	12
22	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.4	0
23	Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity. <i>Modern Rheumatology</i> , 2020, 30, 172-177.	0.9	13
24	Risk of Wnt/ β -catenin signalling pathway gene polymorphisms in primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 418-425.	0.9	9
25	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.5	307
26	Hughes's Stovin syndrome: an uncommon cause of pulmonary aneurysms. <i>Rheumatology</i> , 2020, 59, 2183-2184.	0.9	2
27	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	0.9	54
28	Persistent serological activity in primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 919-923.	1.0	2
29	Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study. <i>Advances in Orthopedics</i> , 2020, 2020, 1-9.	0.4	3
30	IgG4-related kidney disease: experience from a Mexican cohort. <i>Clinical Rheumatology</i> , 2020, 39, 3401-3408.	1.0	11
31	Performance of the 2016 ACR/EULAR SS classification criteria in patients with secondary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 130-133.	0.4	1
32	Omega-3 and omega-6 fatty acids in primary Sjögren's syndrome: clinical meaning and association with inflammation. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 34-39.	0.4	2
33	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.4	2
34	Pan-American League of Associations for Rheumatology (PANLAR) capillaroscopy study group consensus for the format and content of the report in capillaroscopy in rheumatology. <i>Clinical Rheumatology</i> , 2019, 38, 2327-2337.	1.0	12
35	Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. <i>Cytokine</i> , 2019, 119, 95-112.	1.4	21
36	AB1241...MOST PREVALENT COMORBIDITIES IN PRIMARY SJÖGREN'S SYNDROME IN A HISPANIC POPULATION. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	MicroRNA Expression in Cutaneous Lupus: A New Window to Understand Its Pathogenesis. Mediators of Inflammation, 2019, 2019, 1-26.	1.4	9
38	Novel autoantibodies in Sjögren's syndrome: A comprehensive review. Autoimmunity Reviews, 2019, 18, 192-198.	2.5	59
39	Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome. Thrombosis Research, 2019, 174, 141-147.	0.8	19
40	Can nailfold videocapillaroscopy images be interpreted reliably by different observers? Results of an inter-reader and intra-reader exercise among rheumatologists with different experience in this field. Clinical Rheumatology, 2019, 38, 205-210.	1.0	17
41	PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. JCI Insight, 2019, 4, .	2.3	14
42	Î±-enolase is an antigenic target in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 29-35.	0.4	1
43	Elastographic ultrasound: an additional image tool in Sjögren's syndrome. International Journal of Rheumatic Diseases, 2018, 21, 1293-1300.	0.9	23
44	Biopsy-proven renal involvement and prognosis in 13 hispanic patients with primary Sjögren syndrome. Medicina Clínica (English Edition), 2018, 150, 43-48.	0.1	3
45	Autoimmune comorbidity in achalasia patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 203-208.	1.4	31
46	Markedly high salivary and lacrimal CXCL17 levels in primary Sjögren's syndrome. Joint Bone Spine, 2018, 85, 379-380.	0.8	17
47	Afección renal confirmada mediante biopsia y pronóstico en 13 pacientes hispanos con síndrome de Sjögren primario. Medicina Clínica, 2018, 150, 43-48.	0.3	2
48	Coexistence of Amyloidosis and Primary Sjögren's Syndrome: An Overview. Current Rheumatology Reviews, 2018, 14, 231-238.	0.4	26
49	Use and withdrawal of immunosuppressors in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 177-181.	0.4	0
50	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.5	132
51	Perioperative management of patients with antiphospholipid syndrome: a single-center experience. Rheumatology International, 2017, 37, 1159-1164.	1.5	9
52	Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option. Clinical Rheumatology, 2017, 36, 707-711.	1.0	1
53	Hyperviscosity in primary Sjögren's syndrome: clinical implications. International Journal of Rheumatic Diseases, 2017, 20, 84-89.	0.9	8
54	Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators of Inflammation, 2017, 2017, 1-26.	1.4	101

#	ARTICLE	IF	CITATIONS
55	<i>HIF1A</i>(rs11549465) and <i>AKNA</i>(rs10817595) Gene Polymorphisms Are Associated with Primary Sjögren's Syndrome. BioMed Research International, 2017, 2017, 1-8.	0.9	10
56	Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematosus: A Cross-Sectional Study. Mediators of Inflammation, 2016, 2016, 1-15.	1.4	30
57	Usefulness of IgA Anti-Î±-fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjögren Syndrome with Negative Anti-SSA/SSB Antibodies. Journal of Rheumatology, 2016, 43, 1852-1857.	1.0	11
58	Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercise in the management of hip osteoarthritis. Clinical Rehabilitation, 2016, 30, 935-946.	1.0	50
59	High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients. Rheumatology International, 2015, 35, 643-649.	1.5	11
60	Absence of salivary CCL28 in primary Sjögren's syndrome. Rheumatology International, 2015, 35, 1431-1434.	1.5	16
61	Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology, 2015, 54, 441-448.	0.9	15
62	Sarcoidosis: a single hospital-based study in a 24-year period. Revista De Investigacion Clinica, 2015, 67, 33-8.	0.2	8
63	Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2015, 33, 503-8.	0.4	8
64	Main causes and risk factors for hospitalisation in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2015, 33, 721-5.	0.4	6
65	Histopathological environment besides the focus score in Sjögren's syndrome. International Journal of Rheumatic Diseases, 2014, 17, 898-903.	0.9	23
66	Exercise for osteoarthritis of the hip. The Cochrane Library, 2014, 2014, CD007912.	1.5	219
67	Midfoot and forefoot osteoarthritis. Foot, 2014, 24, 128-134.	0.4	23
68	Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross-sectional study. Arthritis Research and Therapy, 2013, 15, R68.	1.6	44
69	Clinimetric methods in Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 2013, 42, 627-639.	1.6	27
70	Predicting Sjogren's syndrome in patients with recent-onset SLE. Rheumatology, 2013, 52, 1438-1442.	0.9	16
71	The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clinical and Experimental Rheumatology, 2013, 31, 382-8.	0.4	27
72	X chromosome monosomy in primary and overlapping autoimmune diseases. Autoimmunity Reviews, 2012, 11, 301-304.	2.5	28

#	ARTICLE	IF	CITATIONS
73	Task Force Report on Non-criteria Manifestations: Thrombocytopenia. , 2012, , 195-206.		0
74	Sjögren's syndrome and pancreatic affection. Reumatología Clínica (English Edition), 2011, 7, 130-134.	0.2	3
75	The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome. Autoimmunity Reviews, 2011, 10, 123-125.	2.5	106
76	Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases. Rheumatology, 2011, 50, 1288-1292.	0.9	39
77	Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood, 2010, 116, 3058-3063.	0.6	52
78	Similarities and Differences Between Primary and Secondary Sjögren's Syndrome. Journal of Rheumatology, 2010, 37, 800-808.	1.0	42
79	Exercise for osteoarthritis of the hip. , 2009, , CD007912.		68
80	Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. Arthritis and Rheumatism, 2008, 58, 130-136.	6.7	69
81	Effect of therapeutic exercise for hip osteoarthritis pain: Results of a meta-analysis. Arthritis and Rheumatism, 2008, 59, 1221-1228.	6.7	149
82	Gout in Renal Allograft Recipients According to the Pretransplant Hyperuricemic Status. Transplantation, 2008, 86, 1543-1547.	0.5	17
83	The role of the X chromosome in immunity and autoimmunity. Autoimmunity Reviews, 2007, 6, 218-222.	2.5	22
84	Polyarticular arthritis secondary to Mycobacterium bovis infection: An unusual clinical presentation. Joint Bone Spine, 2007, 74, 107-109.	0.8	11
85	Chronic Destructive Elbow Arthropathy Associated With Hydroxyapatite Crystals in a Patient With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2006, 12, 194-195.	0.5	3